| Identification | Back Directory | [Name]
2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one | [CAS]
1374743-00-6 | [Synonyms]
2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one
2'-((5-(4-methylpiperazin-1-yl) yridine-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one
Spiro[cyclohexane-1,9'(6'H)-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one, 7',8'-dihydro-2'-[[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino]- | [Molecular Formula]
C24H30N8O | [MDL Number]
MFCD30747890 | [MOL File]
1374743-00-6.mol | [Molecular Weight]
446.55 |
| Hazard Information | Back Directory | [Description]
Trilaciclib is a small molecule, competitive inhibitor of cyclin
dependent kinases 4 and 6 (CDK4/6), with potential antineoplastic and
chemoprotective activities. | [Uses]
Trilaciclib is a CDK4/6 inhibitor with IC50s of 1 nM and 4 nM for CDK4 and CDK6, respectively. | [Mechanism of action]
Trilaciclib is inhibits cyclin-dependant kinase 4 (CDK4) at a
concentration of 1 nmol/L and cyclin-dependent kinase 5 (CDK5) at 4
nmol/L. Inhibition of CDK2, CDK5, and CDK7 is over 1000-fold less at
these concentrations and inhibition of CDK9 is 50-fold less. CDK4 and
CDK5 are expressed in hematopoietic stem cells and progenitor cells.
They are capable of phosphorylating and inactivating the retinoblastoma
protien; a tumor suppressor. When trilaciclib is given to patients with
retinoblastoma protein-null small cell lung cancer, it does not
interfere with the intended chemotherapy induced cytotoxicity of cancer
cells. Inhibition of CDK4 and CDK5 leads to a reversible pause in the
cell cycle in the G1 phase for approximately 16 hours. The temporary
cell cycle arrest prevents chemotherapy induced DNA damage in healthy
cells, reducing the activity of caspases 3 and 7, which reduces
apoptosis of healthy cells. Other studies have shown inhibitors of CDK4
and CDK6 enhance T-cell activation, upregulating major
histocompatibility complex (MHC) class I and II, and stabilize
programmed death-ligand 1 (PD-L1). Together these activities increase
T-cell activity, increase antigen presentation, and sensitize cells to
immune checkpoint inhibitors. | [Pharmacology]
Trilaciclib is indicated to reduce the incidence of chemotherapy induced myelosuppression in patients prior to receiving platinum and etoposide-containing or topotecan-containing
chemotherapy regimens for extensive-stage small cell lung cancer. It
has a short duration of action of approximately 16 hours, and a narrow
therapeutic index. Patients should be counselled regarding the risk of
injection site reactions, hypersensitivity, and interstitial lung
disease. | [Synthesis]
The synthesis of trilaciclib is as follows:
Intermediate 2 (21.1 g, 70 mmol) and 1-methyl-4-(6-aminopyridin-3-yl)piperazine (13.4 g, 70 mmol) were added to a 100 mL vacuum tube and reacted at 230° C. for 3 h.After the reaction, 300 mL of ethyl acetate was added, washed with water (120 mL) and saturated brine (120 mL) successively, dried with anhydrous sodium sulfate and filtered, the obtained solution was evaporated under reduced pressure to remove the solvent, and the obtained residue was recrystallized with ethanol, 27.5 g of Trilaciclib was obtained with a purity of 99% and a yield of 88%.
| [Drug interactions]
Trilaciclib is indicated to reduce the incidence of chemotherapy induced myelosuppression in patients prior to receiving platinum and etoposide-containing or topotecan-containing chemotherapy regimens for extensive-stage small cell lung cancer. | [storage]
Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
|
| Company Name: |
ExSyn Corp
|
| Tel: |
+91-2240546474 +91-2240546474 |
| Website: |
www.exsyncorp.com |
|